Daewoong Bio Introduces Alzheimer's Blood Test 'Lumipulse' at Symposium for Dementia Specialists

"Strengthening the Foundation for Wider Adoption of Blood-Based Diagnostics"

Daewoong Bio is partnering with LabGenomics to expand the domestic market for Lumipulse, a blood-based diagnostic test for Alzheimer's disease.

Daewoong Bio said on October 12 that it held the FINE Symposium on September 5-6 for physicians specializing in dementia care, where it presented Lumipulse's technical features and potential clinical applications.

Ryu Jaehak, CEO of LabGenomics, explains Lumipulse. Daewoong Bio

Lumipulse is an in vitro diagnostic test that measures pTau217 and amyloid beta (Aβ1-42) in the blood and calculates the ratio of the two biomarkers to assess the likelihood of Alzheimer's disease. It received approval from the U.S. Food and Drug Administration (FDA) in 2025. In clinical trials, it recorded a positive predictive value (PPV) of 91.8% and a negative predictive value (NPV) of 97.3%. Daewoong Bio and LabGenomics believe the blood test could be used to identify patients who need further diagnostic testing, such as amyloid positron emission tomography (PET) scans or cerebrospinal fluid (CSF) tests.

At the symposium, Professor Yang Youngsoon of the Department of Neurology at Soonchunhyang University Cheonan Hospital emphasized the importance of assessing multiple biomarkers together rather than relying on a single biomarker. She explained that comorbidities such as chronic kidney disease and interfering factors in the blood can affect a single pTau measurement, and that assessing the ratio of pTau217 to Aβ1-42 can help address the limitations of individual biomarkers.

Daewoong Bio plans to expand its diagnostic business by leveraging its sales and marketing capabilities in the central nervous system (CNS) field. In partnership with LabGenomics, it aims to bring blood-based Alzheimer's disease testing into clinical practice in Korea, drawing on the company's diagnostic technology and testing infrastructure.

LabGenomics CEO Ryu Jaehak said, "Lumipulse has the advantage of providing more precise diagnostic results through its ratio-based measurement approach. Building on FDA approval data and our testing infrastructure in the United States, we will work with Daewoong Bio to expand the domestic Alzheimer's disease diagnostics market." A Daewoong Bio representative said, "We will work to expand the market for blood-based Alzheimer's disease diagnostics, drawing on our sales and marketing capabilities in the central nervous system field and LabGenomics' diagnostic technology."

This content was produced with the assistance of AI translation services.